2015年3月18日讯/生物谷BIOON/--预计到2019年，亚洲医药市场的两大龙头——印度和日本增幅将分别达到11%和8%，而中国仅仅在今年就能达到12%的记录
根据近来各种研究机构报告的有限资料提示，中国整体的制药市场、印度原料药市场以及日本仿制药市场将成为亚洲医药市场的三大主导龙头。
一份与中国制药市场相关的报告统计，今年中国制药市场将增加到1102.6亿美元，整体医疗行业则预计增长13.5%。撇开大陆市场，另一份关于香港的报告预估其制药市场将在今年达到17亿美元，增长8.5%，医疗市场则增长7%。
根据对印度和日本市场的长期追踪报告显示，从2014年起到2019年，印度期望通过发力原料药市场达到10.76%的年复合增长率。报告称，经过今年短暂的过渡时期，整个印度的医药市场将达到健康增长的状态。
日本仿制药市场的预测则略显保守，从今年起至2019年，年复合增长率只有8.16%。同时，这个市场的份额将被六大龙头分割，分别为明治制药株式会（Meiji Seika Pharma）、 日医工株式会（Nichi-Iko）、Nipro Pharma、沢井制药（Sawai）、梯瓦（Teva ）和Towa。
其他报告称，日本整体的制药市场增长也并不乐观，预计到2020年达到798亿美元，年复合增长率仅为1.8%。尽管日本政府呼吁仿制药取代品牌药，但依靠新药（仿制药）驱动发展所占的百分比也微乎其微。
报告还预测随着全民医保覆盖范围的扩大，日本的医疗器械市场将在2020年以6.1%的增长率达到750亿美元。
信源：FiercePharm
The driving pharmaceutical segments of two of Asia's pharmaceutical giants, India and Japan, are expected to grow at rates of nearly 11% and 8% respectively through the year 2019, and China is expected to record a near-12% increase in this year alone.
Limited information from a series of recent reports by various research companies focused on the overall China pharma market, India's active pharmaceutical ingredients market and Japan's generics markets for clues to what lies ahead for the industry in Asia's three biggest markets.
One report pegged China's pharmaceutical market to increase to $110.26 billion this year, for a growth of 11.7% in U.S. dollar terms. The nation's overall healthcare industry was forecast to grow 13.5% this year.
Just off the China mainland, Hong Kong's figures reported in another forecast had its pharmaceutical market increasing to nearly $1.7 billion this year, for an 8.5% growth, its overall healthcare market expanding by 7%.
Longer-term forecasts were published for India and Japan. India's centered on its API market expected to achieve a compound annual growth rate of 10.76% from last year through 2019. Over a shorter period, through this year, its overall market was expected to achieve healthy growth, a report said.
Japan's generics market outlook through 2019 looked a bit more reserved, with only an 8.16% CAGR from this year through 2019. In that report, Meiji Seika Pharma, Nichi-Iko, Nipro Pharma, Sawai, Teva ($TEVA) and Towa were named as the six leaders of that market segment.
Japan's overall pharmaceutical industry was not expected to fare as well, according to other reports, one forecasting it to reach $79.8 billion by 2020, a CAGR of only 1.8%. Even as the government emphasizes prescribing generics instead of branded drugs, new drugs were expected to drive even that relatively small growth percentage.
One report also forecast Japan's medical-device segment to grow at a 6.1% rate to $75 billion in 2020, crediting the nation's universal health care coverage for the increase.